腎臓病治療薬の世界市場レポート 2025年

腎臓病治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.6％で、230億4,000万米ドルに成長します。予測期間の成長は、新たな治療法や薬剤の革新、精密医療と個別化治療アプローチ、ヘルスケア支出の増加、テレヘルスと遠隔患者モニタリング、世界ヘルスイニシアチブに起因しています。予測期間における主な動向としては、共同研究やパートナーシップ、透析技術の進歩、治療方法の進歩、早期診断と早期介入の重視の高まり、腎臓内科管理における技術統合などが挙げられます。

慢性腎臓病の有病率の拡大は、腎臓病治療薬市場の成長を促進すると予測されます。慢性腎臓病は、徐々に腎臓が損傷し、血液ろ過機能が低下し、体内に老廃物が蓄積する可能性があります。腎臓病治療薬はこの状態を管理する上で重要な役割を果たし、腎機能を改善し、病気の進行を遅らせることを目的としています。2022年7月に米国疾病予防管理センターから発表された報告によると、米国における慢性腎臓病の患者数は3,700万人を超え、主に65歳以上の高齢者が罹患していると推定されています。同様に、カナダ腎臓財団（Kidney Foundation of Canada）は、400万人のカナダ人が腎臓病と闘っていると報告しており、中でも糖尿病は腎不全の顕著な原因となっており、この傾向はさらに高まると予想されています。

糖尿病と高血圧の罹患率の増加は、腎臓病治療薬市場を前進させることになると思われます。糖尿病はインスリン関連の問題による高血糖を特徴とし、高血圧は一貫して高血圧を示し、ますます蔓延している疾患です。両疾患はしばしば腎合併症を引き起こし、腎臓病治療薬に対する需要の高まりを生み出しています。特に、世界保健機関（WHO）の2022年6月のデータでは、1万5,000の医療機関で250万人以上の高血圧患者が登録されており、一方、米国疾病管理センターの2022年の報告書では、推定3,730万人の世界の糖尿病患者が確認されています。その結果、糖尿病と高血圧の蔓延が、腎臓の問題との関連から腎臓病治療薬の需要を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界腎臓病治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の腎臓病治療薬市場：成長率分析
• 世界の腎臓病治療薬市場の実績：規模と成長, 2019-2024
• 世界の腎臓病治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界腎臓病治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腎臓病治療薬市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 降圧剤
• 赤血球生成刺激剤
• 利尿剤
• ACE阻害薬
• 抗糖尿病薬
• その他の薬物
• 世界の腎臓病治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の腎臓病治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の腎臓病治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の腎臓病治療薬市場、降圧剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• カルシウムチャネル遮断薬
• ベータ遮断薬
• アンジオテンシンII受容体拮抗薬（ARB）
• 世界の腎臓病治療薬市場赤血球造血刺激因子のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エポエチンアルファ
• ダルベポエチンアルファ
• 世界の腎臓病治療薬市場利尿薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ループ利尿薬
• チアジド系利尿薬
• カリウム保持性利尿薬
• 世界の腎臓病治療薬市場ACE阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リシノプリル
• エナラプリル
• 世界の腎臓病治療薬市場、抗糖尿病薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトホルミン
• インスリン
• 世界の腎臓病治療薬市場、その他の医薬品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• リン酸結合剤
• ビタミンD類似体
• レニン阻害剤

第7章 地域別・国別分析

• 世界の腎臓病治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腎臓病治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腎臓病治療薬市場：競合情勢
• 腎臓病治療薬市場：企業プロファイル
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Akebia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• FibroGen Inc.
• Johnson And Johnson
• Pfizer Inc.
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Limited
• Boehringer Ingelheim International GmbH
• Reata Pharmaceuticals Inc.
• Ardelyx Inc.
• Novo Nordisk A/S
• Novartis AG
• Baxter International Inc.
• Bristol Myers Squibb Company
• Kissei Pharmaceutical Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Mallinckrodt Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腎臓病治療薬市場2029：新たな機会を提供する国
• 腎臓病治療薬市場2029：新たな機会を提供するセグメント
• 腎臓病治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Nephrology drugs, also known as renal drugs, are medications primarily aimed at kidney care, often targeting high blood pressure and hypertension. They're employed to improve kidney function and slow down disease progression, minimizing further harm to the body.

Key drug types in nephrology include antihypertensive agents, erythropoiesis-stimulating agents, diuretics, ACE inhibitors, antidiabetic agents, and others. Antihypertensive drugs, for instance, are a diverse class used to manage high blood pressure, offering various mechanisms of action. These medications are administered through different routes such as oral, parenteral, and others, and are distributed through hospital pharmacies, online platforms, and retail pharmacies. Major users include hospitals, homecare settings, specialty clinics, and various other end-users.

The nephrology drug market research report is one of a series of new reports from The Business Research Company that provides nephrology drug market statistics, including nephrology drug industry global market size, regional shares, competitors with a nephrology drug market share, detailed nephrology drug market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology drug industry. This nephrology drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nephrology drugs market size has grown strongly in recent years. It will grow from$16.88 billion in 2024 to $17.86 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising prevalence of chronic kidney diseases (CKD), advancements in drug development, increasing awareness and diagnosis, government initiatives and healthcare policies, increasing incidence of diabetes

The nephrology drugs market size is expected to see strong growth in the next few years. It will grow to $23.04 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, precision medicine and personalized treatment approaches, increasing healthcare expenditure, telehealth and remote patient monitoring, global health initiatives. Major trends in the forecast period include collaborations and partnerships, technological advancements in dialysis, advancements in treatment modalities, growing emphasis on early diagnosis and intervention, technological integration in nephrology management.

The expanding prevalence of chronic kidney disease is anticipated to drive growth in the nephrology drugs market. Chronic kidney disease results from gradual kidney damage, leading to reduced blood filtration and potential waste buildup in the body. Nephrology drugs play a vital role in managing this condition, aiming to improve kidney function and slow disease progression. Notably, reports from the Centers for Disease Control and Prevention in July 2022 estimated over 37 million diagnosed cases of chronic kidney disease in the US, primarily affecting individuals aged 65 or older. Similarly, the Kidney Foundation of Canada reported 4 million Canadians grappling with kidney diseases, with diabetes being a prominent contributor to kidney failure, a trend expected to rise further.

The rising incidence of diabetes and hypertension is set to propel the nephrology drug market forward. Diabetes, characterized by high blood glucose levels due to insulin-related issues, and hypertension, denoting consistently high blood pressure, are increasingly prevalent conditions. Both ailments often lead to renal complications, creating a heightened demand for nephrology medications. Notably, the World Health Organization's June 2022 data registered over 2.5 million hypertension patients across 15,000 health institutions, while the Centers for Disease Control's 2022 report identified an estimated 37.3 million global cases of diabetes. Consequently, the prevalence of diabetes and hypertension drives the demand for nephrology drugs due to their association with kidney issues.

Product innovation stands as a prominent trend shaping the nephrology drug market. Key industry players are actively introducing novel drugs and solutions to maintain market relevance. For instance, in March 2022, Zydus Lifesciences Limited launched Oxemia (desidustat), an oral medication for chronic kidney disease. This innovative small-molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor has shown promise in Phase III trials, exhibiting positive safety profiles and beneficial effects on anemia, iron mobilization, and LDL-C reduction in CKD patients. Additionally, this innovation is positioned to alleviate the disease burden by providing cost-effective treatment and enhancing patients' quality of life.

Major companies in the nephrology drugs market prioritize obtaining approvals for innovative products, such as the US Food and Drug Administration's approval of Jardiance (empagliflozin). This medication, belonging to the SGLT-2 family for type 2 diabetes, enhances glucose excretion via the kidneys. In January 2023, Eli Lilly and Company, in collaboration with Boehringer Ingelheim, announced FDA approval of Jardiance tablets. These tablets are being investigated as a potential treatment to reduce the risk of advancing kidney disease and cardiovascular death in adults with chronic kidney disease, signifying a concerted effort among pharmaceutical giants to address evolving consumer needs through innovation and regulatory milestones.

In January 2024, Novartis AG, a pharmaceutical company based in Switzerland, acquired SanReno Therapeutics for an undisclosed amount. This acquisition highlights Novartis' dedication to expanding its renal market portfolio, especially in Greater China and Singapore, where there is considerable growth potential for nephrology therapeutics. The strategic decision aligns with Novartis' broader objectives of developing innovative treatments for kidney diseases, thereby strengthening its competitive position in the nephrology drugs market. SanReno Therapeutics is a clinical-stage biotechnology company based in China that specializes in creating innovative therapies for kidney diseases, with a particular focus on Immunoglobulin A Nephropathy (IgAN).

Major companies operating in the nephrology drugs market include AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., F. Hoffmann-La Roche AG, FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Amicus Therapeutics, Chugai Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Mylan N.V., Endo Pharmaceuticals plc

North America was the largest region in the nephrology drug market in 2024. Europe will be the second-largest growing region in the nephrology drug market in 2024. The regions covered in the nephrology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the nephrology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The nephrology drugs market consists of sales of invokana, phoslo, renvela, sensipar, and procrit drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nephrology Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nephrology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nephrology drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nephrology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Antihypertensive Agents; Erythropoiesis-Stimulating Agents; Diuretics; ACE Inhibitors; Antidiabetic Agents; Other Drugs
• 2) By Route Of Administration: Oral; Parenteral; Other Route Of Administration
• 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Antihypertensive Agents: Calcium Channel Blockers; Beta-Blockers; Angiotensin II Receptor Blockers (ARBs)
• 2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa; Darbepoetin Alfa
• 3) By Diuretics: Loop Diuretics; Thiazide Diuretics; Potassium-Sparing Diuretics
• 4) By ACE Inhibitors: Lisinopril; Enalapril
• 5) By Antidiabetic Agents: Metformin; Insulin
• 6) By Other Drugs: Phosphate Binders; Vitamin D Analogues; Renin Inhibitors
• Companies Mentioned: AstraZeneca plc; AbbVie Inc.; Akebia Therapeutics Inc.; Amgen Inc.; F. Hoffmann-La Roche AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nephrology Drugs Market Characteristics

3. Nephrology Drugs Market Trends And Strategies

4. Nephrology Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Nephrology Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nephrology Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nephrology Drugs Market Growth Rate Analysis
• 5.4. Global Nephrology Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nephrology Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nephrology Drugs Total Addressable Market (TAM)

6. Nephrology Drugs Market Segmentation

• 6.1. Global Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antihypertensive Agents
• Erythropoiesis-Stimulating Agents
• Diuretics
• ACE Inhibitors
• Antidiabetic Agents
• Other Drugs
• 6.2. Global Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administration
• 6.3. Global Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.4. Global Nephrology Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Nephrology Drugs Market, Sub-Segmentation Of Antihypertensive Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Calcium Channel Blockers
• Beta-Blockers
• Angiotensin II Receptor Blockers (ARBs)
• 6.6. Global Nephrology Drugs Market, Sub-Segmentation Of Erythropoiesis-Stimulating Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epoetin Alfa
• Darbepoetin Alfa
• 6.7. Global Nephrology Drugs Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Loop Diuretics
• Thiazide Diuretics
• Potassium-Sparing Diuretics
• 6.8. Global Nephrology Drugs Market, Sub-Segmentation Of ACE Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lisinopril
• Enalapril
• 6.9. Global Nephrology Drugs Market, Sub-Segmentation Of Antidiabetic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metformin
• Insulin
• 6.10. Global Nephrology Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Phosphate Binders
• Vitamin D Analogues
• Renin Inhibitors

7. Nephrology Drugs Market Regional And Country Analysis

• 7.1. Global Nephrology Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nephrology Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nephrology Drugs Market

• 8.1. Asia-Pacific Nephrology Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nephrology Drugs Market

• 9.1. China Nephrology Drugs Market Overview
• 9.2. China Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nephrology Drugs Market

• 10.1. India Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nephrology Drugs Market

• 11.1. Japan Nephrology Drugs Market Overview
• 11.2. Japan Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nephrology Drugs Market

• 12.1. Australia Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nephrology Drugs Market

• 13.1. Indonesia Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nephrology Drugs Market

• 14.1. South Korea Nephrology Drugs Market Overview
• 14.2. South Korea Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nephrology Drugs Market

• 15.1. Western Europe Nephrology Drugs Market Overview
• 15.2. Western Europe Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nephrology Drugs Market

• 16.1. UK Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nephrology Drugs Market

• 17.1. Germany Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nephrology Drugs Market

• 18.1. France Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nephrology Drugs Market

• 19.1. Italy Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nephrology Drugs Market

• 20.1. Spain Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nephrology Drugs Market

• 21.1. Eastern Europe Nephrology Drugs Market Overview
• 21.2. Eastern Europe Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nephrology Drugs Market

• 22.1. Russia Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nephrology Drugs Market

• 23.1. North America Nephrology Drugs Market Overview
• 23.2. North America Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nephrology Drugs Market

• 24.1. USA Nephrology Drugs Market Overview
• 24.2. USA Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nephrology Drugs Market

• 25.1. Canada Nephrology Drugs Market Overview
• 25.2. Canada Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nephrology Drugs Market

• 26.1. South America Nephrology Drugs Market Overview
• 26.2. South America Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nephrology Drugs Market

• 27.1. Brazil Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nephrology Drugs Market

• 28.1. Middle East Nephrology Drugs Market Overview
• 28.2. Middle East Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nephrology Drugs Market

• 29.1. Africa Nephrology Drugs Market Overview
• 29.2. Africa Nephrology Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nephrology Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nephrology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nephrology Drugs Market Competitive Landscape And Company Profiles

• 30.1. Nephrology Drugs Market Competitive Landscape
• 30.2. Nephrology Drugs Market Company Profiles
  • 30.2.1. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Akebia Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Nephrology Drugs Market Other Major And Innovative Companies

• 31.1. FibroGen Inc.
• 31.2. Johnson And Johnson
• 31.3. Pfizer Inc.
• 31.4. GlaxoSmithKline plc
• 31.5. Teva Pharmaceutical Industries Limited
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Reata Pharmaceuticals Inc.
• 31.8. Ardelyx Inc.
• 31.9. Novo Nordisk A/S
• 31.10. Novartis AG
• 31.11. Baxter International Inc.
• 31.12. Bristol Myers Squibb Company
• 31.13. Kissei Pharmaceutical Co. Ltd.
• 31.14. Kyowa Kirin Co. Ltd.
• 31.15. Mallinckrodt Pharmaceuticals

32. Global Nephrology Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nephrology Drugs Market

34. Recent Developments In The Nephrology Drugs Market

35. Nephrology Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Nephrology Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nephrology Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nephrology Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer